title: [Medical treatment of the Raynaud phenomenon].
abstract: The medical treatment of Raynaud's phenomenon must be adapted to each particular case. Benign cases do not require drug therapy. Various substances seem able to relieve the most severe cases (calcium blockers, alpha-blockers). Prostaglandins perfusions and plasmaphoresis must be reserved for the most severe cases, with trophic disorders not improved with less aggressive treatments.
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors; D001676:Biofeedback, Psychology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006801:Humans; D007650:Ketanserin / Q000627:therapeutic use; D010956:Plasmapheresis; D011224:Prazosin / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D011928:Raynaud Disease / Q000628:therapy*; D012110:Reserpine / Q000627:therapeutic use
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D011453:Prostaglandins; D012110:Reserpine; D007650:Ketanserin; D011224:Prazosin
vernacular_title: Traitement médical du phénomène de Raynaud.